Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Effect of Inflammation in Heart Failure

Phase 2

Withdrawn

Conditions: Heart Failure
Inflammation
Myocardial Dysfunction

Interventions: Device: MRI scan
Drug: Dapagliflozin
Device: CMR imaging

First Posted Date: 2022-04-15

Last Posted Date: 2022-06-27

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT05330013

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies

Recruiting

Conditions: Mortality in Sickle Cell
Sickle Cell Life Expectancy and Risk Factors for Early Death
Sickle Cell Organ Damage
Sickle Cell Lung Disease and Sudden Death
Sickle Cell Cardiopulmonary Complications

First Posted Date: 2022-01-28

Last Posted Date: 2025-04-10

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 200

Registration Number: NCT05213572

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Vaccine Responses in Patients With B Cell Malignancies

Phase 4

Recruiting

Conditions: Lymphoma

Interventions: Biological: Fluzone
Biological: Shingrix
Biological: Flucelvax
Biological: Afluria
Biological: PREVNAR 13
Biological: Heplisav -B
Biological: Pfizer-COVID-19 Vaccine
Biological: FluLaval
Biological: Fluarix
Biological: PNEUMOVAX 23
Drug: PREVNAR 20
Drug: AREXVY, ABRYSVO

First Posted Date: 2021-12-28

Last Posted Date: 2025-06-03

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 500

Registration Number: NCT05170399

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Natural History Study of CADASIL

Recruiting

Conditions: Arterial Stiffness
Germline Mutation in the NOTCH 3 Gene
Cardiovascular Disease
Pathogenesis of CADASIL
Clinical Phenotype of CADASIL

Interventions: Device: MRI

First Posted Date: 2021-10-11

Last Posted Date: 2025-07-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 155

Registration Number: NCT05072483

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung

Early Phase 1

Completed

Conditions: Latent Tuberculosis Infection (LTBI)
Healthy

Interventions: Drug: Tuberculin Purified Protein Derivative

First Posted Date: 2021-08-31

Last Posted Date: 2025-01-22

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 18

Registration Number: NCT05027958

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

Recruiting

Conditions: Inherited Bone Marrow Failure Syndromes
Telomere Biology Disorders
Severe Aplastic Anemia

First Posted Date: 2021-08-19

Last Posted Date: 2025-06-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1000

Registration Number: NCT05012111

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Technical Development of Cardiovascular Magnetic Resonance Imaging

Recruiting

Conditions: Cardiovascular Disease

First Posted Date: 2021-06-16

Last Posted Date: 2025-06-29

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 3400

Registration Number: NCT04927429

Locations: 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Effect of Chronic Inflammation on Myocardial Perfusion and Function

Terminated

Conditions: Psoriasis

Interventions: Drug: 13N Amonia

First Posted Date: 2021-05-04

Last Posted Date: 2023-04-06

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 16

Registration Number: NCT04870827

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT)

Completed

Conditions: Familial LCAT Deficiency

Interventions: Drug: Recombinant LCAT

First Posted Date: 2021-02-04

Last Posted Date: 2025-06-10

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1

Registration Number: NCT04737720

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Anti-Inflammatory Effects of Time-Restricted Feeding

Completed

Conditions: Systemic Inflammation
Psoriasis

First Posted Date: 2021-01-28

Last Posted Date: 2025-06-12

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 27

Registration Number: NCT04728165

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy